



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Enurev Breezhaler

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency's update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type IB /	C.I HUMAN AND VETERINARY MEDICINAL	06/08/2025		SmPC,	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/VR/0000280416	<p>PRODUCTS - C.I.z Implementation of QRD template - Accepted</p> <p>C.I.z. - to update section 6.1 of the SmPC and section 6 of the Package Leaflet to add to the list of excipients the complete components of capsule shell and printing ink, under a separate heading "Capsule Shell".</p>			Labelling and PL	
Variation type IA / EMA/VR/0000272066	<p>A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted</p> <p>B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.a Tightening of in-process limits - Accepted</p>	21/05/2025	N/A		